Zacks: Brokerages Expect Galectin Therapeutics Inc. (NASDAQ:GALT) to Announce -$0.09 EPS

Analysts expect that Galectin Therapeutics Inc. (NASDAQ:GALT) will post ($0.09) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have provided estimates for Galectin Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.07) and the lowest estimate coming in at ($0.10). Galectin Therapeutics posted earnings of ($0.07) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 28.6%. The business is expected to issue its next quarterly earnings results on Tuesday, November 12th.

On average, analysts expect that Galectin Therapeutics will report full-year earnings of ($0.37) per share for the current fiscal year, with EPS estimates ranging from ($0.47) to ($0.27). For the next fiscal year, analysts forecast that the business will report earnings of ($0.46) per share, with EPS estimates ranging from ($0.51) to ($0.41). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Galectin Therapeutics.

Galectin Therapeutics (NASDAQ:GALT) last announced its earnings results on Friday, August 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.04.

A number of brokerages recently issued reports on GALT. Zacks Investment Research upgraded shares of Galectin Therapeutics from a “hold” rating to a “buy” rating and set a $3.75 price target for the company in a research note on Thursday, August 15th. ValuEngine downgraded shares of Galectin Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, May 18th.

Shares of GALT stock traded up $0.20 during mid-day trading on Friday, reaching $3.79. 239,689 shares of the company were exchanged, compared to its average volume of 348,271. Galectin Therapeutics has a fifty-two week low of $2.94 and a fifty-two week high of $6.98. The company has a market capitalization of $215.76 million, a P/E ratio of -9.97 and a beta of 3.04. The business’s 50 day simple moving average is $3.44 and its 200 day simple moving average is $4.17.

Hedge funds have recently modified their holdings of the company. Amussen Hunsaker Associates LLC acquired a new position in Galectin Therapeutics in the second quarter worth about $71,000. Cambridge Investment Research Advisors Inc. raised its stake in Galectin Therapeutics by 32.0% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 232,554 shares of the company’s stock valued at $965,000 after buying an additional 56,332 shares in the last quarter. Centaurus Financial Inc. raised its stake in Galectin Therapeutics by 20,098.8% during the second quarter. Centaurus Financial Inc. now owns 16,563 shares of the company’s stock valued at $69,000 after buying an additional 16,481 shares in the last quarter. D. E. Shaw & Co. Inc. lifted its holdings in Galectin Therapeutics by 19.3% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 19,498 shares of the company’s stock worth $81,000 after buying an additional 3,148 shares during the last quarter. Finally, Vivaldi Capital Management LLC bought a new position in Galectin Therapeutics during the 2nd quarter worth approximately $44,000. 14.99% of the stock is currently owned by institutional investors and hedge funds.

Galectin Therapeutics Company Profile

Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate includes GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.

Featured Article: Gap Up Stocks

Get a free copy of the Zacks research report on Galectin Therapeutics (GALT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Galectin Therapeutics (NASDAQ:GALT)

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.